Sotac Pharmaceuticals Limited reported a consolidated net profit of ₹576.67 lakh for the financial year ended March 31, 2026, on revenue from operations of ₹10,123.93 lakh. The Board of Directors, led by Chairman and Managing Director Sharadkumar Dashrathbhai Patel, approved the audited standalone and consolidated financial results at a board meeting held on May 26, 2026. The board also recommended a final dividend of ₹0.20 per equity share, representing 2.00% of the face value of ₹10 per share, subject to shareholder approval at the ensuing Annual General Meeting.

The statutory auditors, M/s. Keyur Shah & Co. Chartered Accountants (FRN: 141173W), issued an audit report with an unmodified opinion on both the standalone and consolidated financial results. The consolidated financial statements include results from three subsidiaries: Sotac Healthcare Private Limited (71.00% holding), Sotac Research Private Limited (100.00% holding), and Sotac Lifesciences Private Limited (55.77% holding). For the year ended March 31, 2026, the Group's share of total assets from these subsidiaries stood at ₹6,753.28 lakh, total revenue at ₹3,942.60 lakh, and total net profit after tax at ₹140.28 lakh.

Consolidated Financial Performance

On a consolidated basis, total income for FY26 stood at ₹10,158.63 lakh compared to ₹10,088.34 lakh in the previous year. Total expenses for the period amounted to ₹9,288.78 lakh, against ₹8,976.33 lakh in the prior year. Profit before tax was ₹869.63 lakh, with total tax expense of ₹240.30 lakh. Net profit attributable to the parent after minority interest stood at ₹576.67 lakh, compared to ₹802.67 lakh in the prior year. Basic and diluted earnings per share (EPS) for the year were ₹5.22, down from ₹7.26 in the previous year.

Standalone Financial Performance

On a standalone basis, revenue from operations rose to ₹7,187.95 lakh in FY26 from ₹6,238.42 lakh in FY25. Total standalone income for the year was ₹7,397.79 lakh compared to ₹6,475.92 lakh in the prior year. Standalone profit before tax stood at ₹692.45 lakh, with total tax expense of ₹200.63 lakh. Standalone net profit for the year was ₹491.82 lakh, compared to ₹477.17 lakh in the previous year. Standalone basic and diluted EPS for FY26 was ₹4.45, against ₹4.32 in FY25.

Balance Sheet Highlights

The consolidated balance sheet as at March 31, 2026 reflected total assets and total equity and liabilities of ₹13,347.04 lakh, compared to ₹12,432.82 lakh in the prior year. Shareholders' funds stood at ₹5,887.48 lakh, with reserves and surplus at ₹4,782.48 lakh. Minority interest was recorded at ₹569.70 lakh. On a standalone basis, total equity and liabilities as of March 31, 2026 stood at ₹9,460.77 lakh, with reserves and surplus at ₹4,677.04 lakh, up from ₹4,197.94 lakh in the prior year.

Cash Flow Summary

On a consolidated basis, net cash generated from operations for the year was ₹1,686.70 lakh, compared to a net outflow of ₹433.18 lakh in the prior year. Net cash used in investing activities was ₹689.76 lakh, while net cash used in financing activities was ₹1,035.53 lakh. Cash and cash equivalents as on March 31, 2026 stood at ₹117.80 lakh, down from ₹156.39 lakh at the beginning of the year. On a standalone basis, net cash generated from operations was ₹1,214.96 lakh, and cash and cash equivalents at the end of the year stood at ₹33.91 lakh.

The company is primarily engaged in the manufacturing of a wide range of pharmaceutical products, including Non Beta-Lactam (general) tablets, capsules, syrups, and external preparations. As the company operates under a single business segment, segment reporting is not applicable. There were no investor complaints pending, received, disposed, or resolved during the year ended March 31, 2026.